help button home button Endocrine Society JCEM ENDO 08
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Patton, P. E.
Right arrow Articles by Zelinski-Wooten, M. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patton, P. E.
Right arrow Articles by Zelinski-Wooten, M. B.

Journal of Clinical Endocrinology & Metabolism, Vol 70, 1213-1218, Copyright © 1990 by Endocrine Society

ARTICLES

The effect of intraluteal infusion of deglycosylated human chorionic gonadotropin on the corpus luteum in rhesus monkeys

PE Patton, RL Stouffer and MB Zelinski-Wooten
Department of Obstetrics and Gynecology, Oregon Health Sciences Center, Portland 97201.

Removal of the carbohydrates from hCG results in an antagonist (degly- hCG) that competitively inhibits hCG/LH-stimulated adenylate cyclase in macaque luteal tissue in vitro, but its effect in vivo is controversial. To examine the effect of degly-hCG on the lifespan and steroidogenic activity of the primate corpus luteum, the antagonist was administered to female rhesus monkeys (n = 7) beginning at the midluteal phase of the menstrual cycle. In a control cycle the saline vehicle was infused via an osmotic minipump directly into the corpus luteum. In a subsequent cycle, one of three dose rates of degly-hCG (0.001, 0.009, and 0.09 nmol/h) was infused into the corpus luteum. Pump implantation and infusion began 5-9 days after the midcycle LH surge and continued for 7 days. Peripheral venous blood was collected daily from day 8 of the cycle until menses, and serum progesterone levels were determined by RIA. Progesterone levels and patterns were similar in animals that received either the saline vehicle or degly- hCG, and the length of the luteal phase in monkeys receiving any dose of degly-hCG (16.4 +/- 0.5 days) was not different from that in animals receiving a control infusion (16.1 +/- 0.9 days). In a corollary study, an intraluteal infusion of degly-hCG (0.009 nmol/h) in the midluteal phase did not prevent stimulation of progesterone levels after im injection of hCG (15 IU/day for 5 days). We conclude that whereas degly- hCG is a useful tool to examine gonadotropin action in vitro, it is not a potent gonadotropin antagonist in vivo.


This article has been cited by other articles:


Home page
 Hum ReprodHome page
J. W. Wright, T. Pejovic, J. Fanton, and R. L. Stouffer
Induction of proliferation in the primate ovarian surface epithelium in vivo
Hum. Reprod., January 1, 2008; 23(1): 129 - 138.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1990 by The Endocrine Society